Close Menu

This article has been updated to include comments from NeoGenomics' earnings call.

NEW YORK (GenomeWeb) – NeoGenomics today reported a 142 percent increase in its third quarter revenues on continued growth in clinical genetic testing volume, driven by its acquisition of Clarient.

For the three-month period ended Sept. 30, the company's revenues increased to $60.8 million from $25.1 million in the same period last year, falling just short of analysts' consensus estimate of $61 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.